{
    "2020-03-26": [
        [
            {
                "time": "",
                "original_text": "仁会生物IPO：净利持续亏损销售费用攀升 核心产品仍处市场导入期 亏损",
                "features": {
                    "keywords": [
                        "仁会生物",
                        "IPO",
                        "净利亏损",
                        "销售费用",
                        "核心产品",
                        "市场导入期"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "贝达药业现6笔大宗交易 共成交9,589.50万元",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "大宗交易",
                        "成交金额"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}